Recursion Pharmaceuticals Gestion
Gestion contrôle des critères 1/4
Le PDG Recursion Pharmaceuticals est Najat Khan, nommé en Jan2026, a un mandat de moins d'un an. La rémunération annuelle totale est $ 9.19M, composée du salaire de 3.1% et des bonus 96.9%, y compris les actions et options de la société. détient directement 0.008% des actions de la société, d'une valeur de $ 137.24K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.5 ans et 10.6 ans.
Informations clés
Najat Khan
Directeur général
US$9.2m
Rémunération totale
| Pourcentage du salaire du PDG | 3.10% |
| Durée du mandat du directeur général | less than a year |
| Propriété du PDG | 0.008% |
| Durée moyenne d'occupation des postes de direction | 1.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 10.6yrs |
Mises à jour récentes de la gestion
Recent updates
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat
May 04
Recursion Pharmaceuticals! WTH is going on?
Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Apr 28
RXRX: Later Launch And Higher Costs Will Set Up Cleaner Upside
Analysts have trimmed their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense and share count assumptions, as well as a later expected launch timeline for REC-617. Analyst Commentary Bullish analysts point out that the recent cut to a US$6 price target still reflects confidence in Recursion Pharmaceuticals reaching key development milestones over time, even with updated expense forecasts and a later expected REC-617 launch.Recursion Pharmaceuticals! WTH is going on?
I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!RXRX: Later Launch Assumptions Will Set Up Cleaner Long Term Upside
Analysts recently trimmed their 12 month price target for Recursion Pharmaceuticals to $6 from $7, citing revised operating expense assumptions, a higher share count, and a later expected launch timing for REC-617. Analyst Commentary Recent commentary around Recursion Pharmaceuticals has focused on updated assumptions for operating expenses, a higher share count, and a later expected launch for REC-617.RXRX: Later Launch And Cleaner Model Assumptions Will Support Long Term Upside
Analysts have lowered their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense assumptions, a revised share count, and a later expected launch timing for REC-617. Analyst Commentary While the latest research includes a lower price target, recent commentary still highlights areas where bullish analysts see room for Recursion Pharmaceuticals to execute and create value over time.RXRX: FAP Data And Cautious Outlook Will Support Long Term Thesis
Analysts have trimmed their price target for Recursion Pharmaceuticals to $6 from $7, citing revised estimates, updated operating expense and share count assumptions, and a later expected launch for REC-617. Analyst Commentary Recent commentary points to a more cautious tone on Recursion Pharmaceuticals, with the latest price target reset to reflect updated expense planning, share count expectations, and a later potential launch for REC-617.Recursion Pharmaceuticals! WTH is going on?
As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!
RXRX: FAP Trial Success Will Support Future Margin Expansion Potential
Analysts have maintained their $7.00 price target on Recursion Pharmaceuticals, citing broadly consistent long term assumptions and only minor adjustments to the discount rate, profit margin outlook, and future P/E multiple. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an allosteric MEK1/2 inhibitor being studied for familial adenomatous polyposis, with REC-4881 4 mg QD linked to rapid clinical activity in the trial population (Key Developments).RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have raised their price target on Recursion Pharmaceuticals to US$11.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis.RXRX: Positive FAP Trial Results Will Support Future Margin Expansion
Analysts have modestly adjusted their price target on Recursion Pharmaceuticals, citing updated assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E. Together, these revisions lead to a refined fair value estimate of US$7.00 per share.RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have lifted their fair value estimate for Recursion Pharmaceuticals from US$10.00 to US$11.00, citing updated assumptions around revenue growth, profit margin, and future P/E levels as key drivers of the new target. What's in the News Recursion reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (Key Developments).RXRX: Positive TUPELO Data Will Drive Future AI-Enabled Margin Expansion
Analysts have raised their price target on Recursion Pharmaceuticals by approximately 10 percent to around 7.00 dollars per share, citing a modestly higher fair value estimate despite tempered revenue growth assumptions. What's in the News Announced positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75 percent of evaluable patients showing reduced total polyp burden and a 43 percent median reduction after 12 weeks of treatment (Key Developments).RXRX: New CEO Appointment Will Spark Stronger Margins And AI-Driven Momentum
Analysts have modestly raised their price target for Recursion Pharmaceuticals from $6.30 to $6.33 per share. They cite improved forecasted revenue growth and higher profit margins as key drivers behind the update.RXRX: Leadership Change Will Drive Future Opportunity Amid Accelerating Revenue Outlook
Analysts have lowered their price target for Recursion Pharmaceuticals from $6.47 to $6.30, citing adjustments in projected discount rates and profit margins despite stronger expected revenue growth. What's in the News Dr. Najat Khan has been appointed as Chief Executive Officer of Recursion Pharmaceuticals, effective January 1, 2026 (Key Developments).Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 07Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win
Apr 11Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts
Mar 27
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Mar 12This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Mar 02Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Feb 14Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$560m |
| Dec 31 2025 | n/a | n/a | -US$645m |
| Sep 30 2025 | n/a | n/a | -US$716m |
| Jun 30 2025 | n/a | n/a | -US$649m |
| Mar 31 2025 | n/a | n/a | -US$575m |
| Dec 31 2024 | US$9m | US$285k | -US$464m |
Rémunération vs marché: La rémunération totale de Najat ($USD 9.19M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.48M ).
Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Najat avec les performances de l'entreprise.
PDG
Najat Khan (41 yo)
Dr. Najat Khan, Ph D is Chief Executive Officer and President of Recursion Pharmaceuticals, Inc. January 1, 2026. She was Chief R&D Officer and Chief Commercial Officer of Recursion Pharmaceuticals, Inc. f...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 12.5yrs | US$8.50m | 1.04% $ 18.4m | |
| CEO, President & Director | less than a year | US$9.19m | 0.0077% $ 137.2k | |
| CFO & President of Recursion UK | 1.5yrs | US$8.59m | 0.049% $ 867.4k | |
| Advisor | 2.9yrs | US$1.93m | 0.014% $ 251.2k | |
| Chief Operating Officer | 1.5yrs | pas de données | pas de données | |
| Chief Technology Officer | 6.3yrs | pas de données | pas de données | |
| Chief Scientific Officer | 1.5yrs | pas de données | 0.072% $ 1.3m | |
| Chief Legal Officer & Corporate Secretary | 2.6yrs | pas de données | pas de données | |
| Chief Communications Officer | no data | pas de données | pas de données | |
| Chief People and Impact Officer | 1.5yrs | pas de données | pas de données | |
| Chief Business Officer | 1.5yrs | pas de données | pas de données | |
| Senior Vice President of Clinical Development & Data Science | less than a year | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de RXRX n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 12.5yrs | US$8.50m | 1.04% $ 18.4m | |
| CEO, President & Director | 2.1yrs | US$9.19m | 0.0077% $ 137.2k | |
| Member of Business Advisory Panel | 11.5yrs | pas de données | pas de données | |
| Member of Business Advisory Panel | 11.9yrs | pas de données | pas de données | |
| Chairman of Therapeutics Advisory Board | 4.8yrs | pas de données | pas de données | |
| Vice-Chairman & Lead Independent Director | 6.2yrs | US$316.48k | 0.0098% $ 174.3k | |
| Director | less than a year | US$296.73k | 0.61% $ 10.8m | |
| Independent Director | 13.3yrs | US$294.98k | 1.18% $ 20.9m | |
| Member of Scientific and Technical Advisory Board | 12.1yrs | pas de données | pas de données | |
| Member of Scientific & Technical Advisory Board | 12.1yrs | pas de données | pas de données | |
| Independent Director | 9.7yrs | US$304.23k | 0.024% $ 422.0k | |
| Independent Director | 1.2yrs | pas de données | pas de données |
Conseil d'administration expérimenté: Le conseil d'administration de la RXRX est chevronné et expérimenté ( 10.6 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/06 01:50 |
| Cours de l'action en fin de journée | 2026/05/06 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Recursion Pharmaceuticals, Inc. est couverte par 13 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Gal Munda | Berenberg |
| Gaurav Goparaju | Berenberg |
| Alec Stranahan | BofA Global Research |